Collate raises $95M Series B at near-$1B valuation to automate life sciences paperwork
What's the deal? Collate, a San Francisco-based startup that uses AI to automate life sciences documentation, has raised $95M in a round led by Redpoint VenturesDealroom has a profile for this one. Try Dealroom →. The deal values the company at close to $1B and brings its total funding to $125M.
Founded by two-time entrepreneur Surbhi Sarna — a former Y Combinator partner — Collate has signed roughly 50 customers since launching its first commercial product in May 2025, including large pharmaceutical companies, major medical device makers, and publicly traded biotech firms.
Why now? "Life sciences strategy and documentation is going to be the AI battleground of 2026, the same way it was for legal in 2025," Sarna told Forbes. Legal AI startup Harvey is now worth $11B, and Collate is betting the same wave will hit pharma and biotech.
The timing was deliberate. AI models are now capable enough to handle complex regulatory documents, and many life sciences firms have already tried building in-house AI tools — only to realise they'd be better off outsourcing. Some regulatory submissions run to 10,000 pages, and Collate says it cuts document completion times by 50% to 90%.
"You will get a big pharma company and grow like a weed inside," said Redpoint's Satish Dharmaraj, who led the investment.
What could go wrong? AI hallucinations remain a real risk, especially in an industry where documentation errors can have patient safety consequences. Sarna says Collate's accuracy sits above 90% and often near 97%, and that the company requires human verification before any document is exported from its system.
"That might not sound sexy, but it's important," she said. "I wanted to introduce AI and documentation to the industry in a way that I thought was patient safe."
The signal: Collate's leap from pre-product to near-unicorn in under two years mirrors a pattern playing out across regulated, document-heavy industries — legal AI led the charge, and life sciences, with regulatory submissions that can stretch to 10,000 pages, looks like the next frontier. That Redpoint, First RoundDealroom has a profile for this one. Try Dealroom →, and Conviction Partners backed the company at US$64.7M-plus valuation before it even had a commercial product underscores investor conviction that vertical AI tools in compliance-intensive sectors can scale fast once enterprise procurement cycles kick in.
Read more: Forbes
